[Asia Economy Reporter Hyunseok Yoo] Incon announced on the 9th that its bio-subsidiary, Jaiber, will participate in the '2020 JP Morgan Healthcare Conference' held in San Francisco, USA, for four days starting from the 13th.


Jaiber, invited to the global conference, plans to hold meetings with global investors centered on its lead underwriters Bank of America (BOA) and Merrill Lynch to attract investment for its full-scale Nasdaq listing. The company explained that by attending renowned international healthcare conferences such as JP Morgan Healthcare, it is expanding exchanges with global big pharma and institutional investors (IB) and accelerating final preparations for the Nasdaq listing.


The 38th JP Morgan Healthcare Conference is the world's largest pharmaceutical and bio IR event where pharmaceutical and bio companies and related investors from around the world gather. About 1,500 global companies from approximately 40 countries participate to introduce their pipelines, attract investment, discover partners, build networks, and understand the latest trends in the pharmaceutical and bio markets.


Jaiber, which researches and develops treatments for chronic kidney rare diseases and intractable anti-inflammatory drugs, has scheduled preliminary meetings related to license agreements with multinational pharmaceutical companies including Roche and Lilly, in addition to meetings with global investors.


The new drug for chronic kidney rare diseases, VAR200, has already obtained FDA approval for Phase 2 clinical trials and is expected to start Phase 2 trials in the first quarter. The intractable anti-inflammatory drug IC100 is in the final preclinical stage and is expected to enter Phase 1 clinical trials in the first half of this year.



A company official said, “Jaiber was selected as one of the ‘Top 20 Companies with Innovative Technologies in 2019’ by Business Worldwide Magazine (BWM) last December, gaining global attention, so meaningful results are expected at this conference,” and added, “We will also engage in close networking schedules among C-Level executives.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing